Optimizing Therapy for Acute Myeloid Leukemia

The 10-year overall survival for younger patients with newly diagnosed acute myeloid leukemia has improved threefold in the past 2 decades. This improvement has occurred in large part because of advances in supportive care and efforts to optimize standard induction and consolidation therapies applied in a stratified approach based on predictors of individual patient risk. Innovations in diagnostic technologies have broadened the understanding of key prognostic factors, including cytogenetic and molecular status, which define the extensive interpatient heterogeneity of this clonal disease. Despite this progress, only approximately 25% of patients who experience a complete remission with cytotoxic chemotherapy (50%–70% of patients with newly diagnosed disease) remain disease-free. Efforts to develop novel agents are actively ongoing, particularly for older patients (age ≥ 60), and targeted therapies, for specific subsets of patients are being based on a better understanding of the biology of the disease.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Steven E. Coutre, MD, Department of Medicine, Division of Hematology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305. E-mail: coutre@stanford.edu
  • 1.

    Cancer Facts and Figures. Atlanta, GA: American Cancer Society; 2008.

  • 2.

    PulteDGondosABrennerH. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica2008;93:594600.

    • Search Google Scholar
    • Export Citation
  • 3.

    AppelbaumFRRoweJMRadichJDickJE. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program2001:6286.

  • 4.

    AppelbaumFRGundackerHHeadDR. Age and acute myeloid leukemia. Blood2006;107:34813485.

  • 5.

    LeithCPKopeckyKJGodwinJ. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood1997;89:33233329.

    • Search Google Scholar
    • Export Citation
  • 6.

    BauduerFDucoutLDastugueN. De novo and secondary acute myeloid leukemia in patients over the age of 65: a review of fifty-six successive and unselected cases from a general hospital. Leuk Lymphoma1999;35:289296.

    • Search Google Scholar
    • Export Citation
  • 7.

    GrimwadeDWalkerHOliverF. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood1998;92:23222333.

    • Search Google Scholar
    • Export Citation
  • 8.

    ByrdJCMrozekKDodgeRK. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood2002;100:43254336.

    • Search Google Scholar
    • Export Citation
  • 9.

    FaragSSArcherKJMrozekK. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood2006;108:6373.

    • Search Google Scholar
    • Export Citation
  • 10.

    MarcucciGRadmacherMDMaharryK. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med2008;358:19191928.

  • 11.

    BullingerLDohnerKKranzR. An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Blood2008;111:44904495.

    • Search Google Scholar
    • Export Citation
  • 12.

    SlovakMLKopeckyKJCassilethPA. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood2000;96:40754083.

    • Search Google Scholar
    • Export Citation
  • 13.

    SchlenkRFDohnerKKrauterJ. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med2008;358:19091918.

    • Search Google Scholar
    • Export Citation
  • 14.

    O'DonnellMRAppelbaumFRCoutreSE. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia version 12009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/aml.pdf. Accessed October 6 2008.

    • Search Google Scholar
    • Export Citation
  • 15.

    BacherUHaferlachTSchochC. Implications of NRAS mutations in AML: a study of 2502 patients. Blood2006;107:38473853.

  • 16.

    NeubauerAMaharryKMrozekK. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol2008;26:46034609.

    • Search Google Scholar
    • Export Citation
  • 17.

    ElliottMALitzowMRLetendreLL. Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood2007;110:41724174.

    • Search Google Scholar
    • Export Citation
  • 18.

    SuciuSMandelliFde WitteT. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood2003;102:12321240.

    • Search Google Scholar
    • Export Citation
  • 19.

    BishopJFLowenthalRMJoshuaD. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood1990;75:2732.

  • 20.

    RussoDMalagolaMMartinelliG. Efficacy and toxicity of FLAI vs ICE for induction treatment of newly diagnosed AML patients, younger than 60 years [abstract]. Blood2004;104:Abstract 878.

    • Search Google Scholar
    • Export Citation
  • 21.

    BermanEHellerGSantorsaJ. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood1991;77:16661674.

    • Search Google Scholar
    • Export Citation
  • 22.

    WiernikPHBanksPLCaseDCJr. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood1992;79:313319.

    • Search Google Scholar
    • Export Citation
  • 23.

    VoglerWRVelez-GarciaEWeinerRS. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol1992;10:11031111.

    • Search Google Scholar
    • Export Citation
  • 24.

    A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group. Br J Haematol1998;103:100109.

    • Search Google Scholar
    • Export Citation
  • 25.

    PautasCThomasXMerabetF. Randomized comparison of standard induction with daunorubicin (DNR) for 3 days vs idarubicin (IDA) for 3 or 4 days in AML pts aged 50 to 70 and of maintenance with interleukin 2. Final analysis of the ALFA 9801 study [abstract]. Blood2007;110:Abstract 162.

    • Search Google Scholar
    • Export Citation
  • 26.

    RoweJMNeubergDFriedenbergW. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood2004;103:479485.

    • Search Google Scholar
    • Export Citation
  • 27.

    BishopJFMatthewsJPYoungGA. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood1996;87:17101717.

    • Search Google Scholar
    • Export Citation
  • 28.

    WeickJKKopeckyKJAppelbaumFR. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood1996;88:28412851.

    • Search Google Scholar
    • Export Citation
  • 29.

    BuchnerTHiddemannWWormannB. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood1999;93:41164124.

    • Search Google Scholar
    • Export Citation
  • 30.

    KernWEsteyEH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of three randomized trials. Cancer2006;107:116124.

    • Search Google Scholar
    • Export Citation
  • 31.

    BuchnerTBerdelWESchochC. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol2006;24:24802489.

    • Search Google Scholar
    • Export Citation
  • 32.

    MayerRJDavisRBSchifferCA. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med1994;331:896903.

    • Search Google Scholar
    • Export Citation
  • 33.

    BloomfieldCDLawrenceDByrdJC. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res1998;58:41734179.

    • Search Google Scholar
    • Export Citation
  • 34.

    SteinASO'DonnellMRSlovakML. High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission. Leukemia2000;14:11911196.

    • Search Google Scholar
    • Export Citation
  • 35.

    ByrdJCDodgeRKCarrollA. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol1999;17:37673775.

    • Search Google Scholar
    • Export Citation
  • 36.

    ByrdJCRuppertASMrozekK. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol2004;22:10871094.

    • Search Google Scholar
    • Export Citation
  • 37.

    BloomfieldCDRuppertASMrozekK. Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) study 8461. Ann Hematol2004;83(Suppl 1):S8485.

    • Search Google Scholar
    • Export Citation
  • 38.

    MooreJOGeorgeSLDodgeRK. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B study 9222. Blood2005;105:34203427.

    • Search Google Scholar
    • Export Citation
  • 39.

    AppelbaumFRKopeckyKJTallmanMS. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol2006;135:165173.

    • Search Google Scholar
    • Export Citation
  • 40.

    BuchnerTUrbanitzDHiddemannW. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol1985;3:15831589.

    • Search Google Scholar
    • Export Citation
  • 41.

    RaiKRHollandJFGlidewellOJ. Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood1981;58:12031212.

  • 42.

    CassilethPAHarringtonDPHinesJD. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol1988;6:583587.

    • Search Google Scholar
    • Export Citation
  • 43.

    OhnoRKobayashiTTanimotoM. Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group. Cancer1993;71:38883895.

    • Search Google Scholar
    • Export Citation
  • 44.

    CassilethPALynchEHinesJD. Varying intensity of postremission therapy in acute myeloid leukemia. Blood1992;79:19241930.

  • 45.

    PreislerHDavisRBKirshnerJ. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study. Blood1987;69:14411449.

    • Search Google Scholar
    • Export Citation
  • 46.

    VisaniGOlivieriAMalagolaM. Consolidation therapy for adult acute myeloid leukemia: a systematic analysis according to evidence based medicine. Leuk Lymphoma2006;47:10911102.

    • Search Google Scholar
    • Export Citation
  • 47.

    ReiffersJGaspardMHMaraninchiD. Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial. Br J Haematol1989;72:5763.

    • Search Google Scholar
    • Export Citation
  • 48.

    FerrantADoyenCDelannoyA. Allogeneic or autologous bone marrow transplantation for acute non-lymphocytic leukemia in first remission. Bone Marrow Transplant1991;7:303309.

    • Search Google Scholar
    • Export Citation
  • 49.

    ZittounRAMandelliFWillemzeR. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med1995;332:217223.

    • Search Google Scholar
    • Export Citation
  • 50.

    ReiffersJStoppaAMAttalM. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia1996;10:18741882.

    • Search Google Scholar
    • Export Citation
  • 51.

    HarousseauJLCahnJYPignonB. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood1997;90:29782986.

    • Search Google Scholar
    • Export Citation
  • 52.

    CassilethPAHarringtonDPAppelbaumFR. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med1998;339:16491656.

    • Search Google Scholar
    • Export Citation
  • 53.

    BurnettAKGoldstoneAHStevensRM. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet1998;351:700708.

    • Search Google Scholar
    • Export Citation
  • 54.

    BurnettAKWheatleyKGoldstoneAH. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol2002;118:385400.

    • Search Google Scholar
    • Export Citation
  • 55.

    TsimberidouAMStavroyianniNViniouN. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer2003;97:17211731.

    • Search Google Scholar
    • Export Citation
  • 56.

    BreemsDABoogaertsMADekkerAW. Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. Br J Haematol2005;128:5965.

    • Search Google Scholar
    • Export Citation
  • 57.

    FerrantALabopinMFrassoniS. Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission: a European Group for Bone Marrow Transplantation study. Blood1997;90:29312938.

    • Search Google Scholar
    • Export Citation
  • 58.

    CornelissenJJvan PuttenWLVerdonckLF. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?Blood2007;109:36583666.

    • Search Google Scholar
    • Export Citation
  • 59.

    JourdanERigal-HuguetFMaritG. One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission. Br J Haematol2005;129:403410.

    • Search Google Scholar
    • Export Citation
  • 60.

    SchlenkRFCorbaciogluAKrauterJ. Gene mutations as predicitive markers for postremission therapy in younger adults with normal karyotype AML [abstract]. Blood2006;108:Abstract 4.

    • Search Google Scholar
    • Export Citation
  • 61.

    PowerMMDi SauroGBrooks-WilsonA. Allogeneic stem cell transplant in first complete remission overcomes the poor prognosis associated with the FLT-3 internal tandem duplication in acute myeloid leukemia [abstract]. Blood2007;110:Abstract 3491.

    • Search Google Scholar
    • Export Citation
  • 62.

    CraddockCFTauroSGregoryJE. Factors predicting long term survival after reduced intensity allogeneic stem cell transplantation in acute myeloid leukemia [abstract]. Blood2007;110:Abstract 326.

    • Search Google Scholar
    • Export Citation
  • 63.

    ValcarcelDMartinoRCaballeroD. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol2008;26:577584.

    • Search Google Scholar
    • Export Citation
  • 64.

    GrimwadeDWalkerHHarrisonG. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood2001;98:13121320.

    • Search Google Scholar
    • Export Citation
  • 65.

    EsteyEHThallPFGilesFJ. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood2002;99:43434349.

    • Search Google Scholar
    • Export Citation
  • 66.

    BuchnerTHiddemannWBerdelWE. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol2003;21:44964504.

    • Search Google Scholar
    • Export Citation
  • 67.

    SieversELLarsonRAStadtmauerEA. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol2001;19:32443254.

    • Search Google Scholar
    • Export Citation
  • 68.

    KujawskiLAGartnerEMRyanI. Gemtuzumab ozogamicin (MylotargR) as primary induction therapy for elderly patients with acute myeloid leukemia: a phase II trial [abstract]. Blood2004;104:Abstract 4508.

    • Search Google Scholar
    • Export Citation
  • 69.

    PirrottaMTBocchiaMBucalossiA. Phase II pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen as induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients [abstract]. Blood2005;106:Abstract 4613.

    • Search Google Scholar
    • Export Citation
  • 70.

    KujawskiLARyanIGriffithKErbaHP. Combination of daunorubicin and cytarabine chemotherapy with gemtuzumab ozogamicin as initial therapy for elderly patients with previously untreated acute myeloid leukemia [abstract]. Blood2005;106:Abstract 4636.

    • Search Google Scholar
    • Export Citation
  • 71.

    BurnettAKKellWJGoldstoneAH. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial [abstract]. Blood2006;108:Abstract 13.

    • Search Google Scholar
    • Export Citation
  • 72.

    FaderlSVerstovsekSCortesJ. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood2006;108:4551.

    • Search Google Scholar
    • Export Citation
  • 73.

    BurnettAKBaccaraniMJohnsonP. A phase II study (Biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute myeloid leukemia for whom standard intensive chemotherapy is not considered suitable [abstract]. Blood2006;108:Abstract 425.

    • Search Google Scholar
    • Export Citation
  • 74.

    GilesFJKantarjianHMCortesJE. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol2003;21:17221727.

    • Search Google Scholar
    • Export Citation
  • 75.

    GilesFVerstovsekSFaderlS. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leuk Res2006;30:15911595.

    • Search Google Scholar
    • Export Citation
  • 76.

    LevisMSmithBDBeranM. A randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition [abstract]. Blood2005;106:Abstract 403.

    • Search Google Scholar
    • Export Citation
  • 77.

    KnapperSBurnettAKLittlewoodT. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood2006;108:32623270.

    • Search Google Scholar
    • Export Citation
  • 78.

    StoneRMFischerTPaquetteR. Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML [abstract]. Blood2005;106:Abstract 404.

    • Search Google Scholar
    • Export Citation
  • 79.

    LancetJEGojoIGotlibJ. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood2007;109:13871394.

    • Search Google Scholar
    • Export Citation
  • 80.

    KarpJEFeldmanEJMorrisL. active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia (AML): phase I trial of oral tipifarnib (T) combined with oral etoposide (E) for adults >= age 70 who are not candidates for traditional cytotoxic chemotherapy (TCC) [abstract]. Blood2006;108:Abstract 426.

    • Search Google Scholar
    • Export Citation
  • 81.

    ListAFKopeckyKJWillmanCL. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood2001;98:32123220.

    • Search Google Scholar
    • Export Citation
  • 82.

    ChaunceyTRRankinCAndersonJE. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia using mitoxantrone, etoposide, and the MDR modulator PSC 833. Leuk Res2000;24:567574.

    • Search Google Scholar
    • Export Citation
  • 83.

    GreenbergPLLeeSJAdvaniR. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol2004;22:10781086.

    • Search Google Scholar
    • Export Citation
  • 84.

    CripeLDLiXLitzowM. A randomized, placebo-controlled, double blind trial of the MDR modulator, zosuquidar, during conventional induction and post-remission therapy for pts > 60 years of age with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): ECOG 3999 [abstract]. Blood2006;108:Abstract 423.

    • Search Google Scholar
    • Export Citation
  • 85.

    LancetJEGotlibJWetzlerM. Phase I/II study of the P-glycoprotein (Pgp) inhibitor zosuquidar administered by continuous infusion (CIV) with daunorubicin (DNR) and cytarabine (ARA-C) as primary therapy in older patients with pgp-positive acute myeloid leukemia (AML) [abstract]. Blood2007;110:Abstract 299.

    • Search Google Scholar
    • Export Citation
  • 86.

    SilvermanLRMcKenzieDRPetersonBL. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol2006;24:38953903.

    • Search Google Scholar
    • Export Citation
  • 87.

    IssaJPGarcia-ManeroGGilesFJ. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood2004;103:16351640.

    • Search Google Scholar
    • Export Citation
  • 88.

    NandSGodwinJSmithS. Azacitidine plus gemtuzumab ozogamicin (GO): a novel combination in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) in the elderly [abstract]. Blood2006;108:Abstract 1981.

    • Search Google Scholar
    • Export Citation
  • 89.

    FrankelALiuJSRizzieriDHoggeD. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma2008;49:543553.

    • Search Google Scholar
    • Export Citation
  • 90.

    Liu-YinJADalySBSaleMA. Minimal residual disease monitoring by RQ-PCR in core binding factor positive AML allows risk-stratification and predicts relapse: results of the UK MRC AML-15 trial [abstract]. Blood2007;110:Abstract 543.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 43 38 13
PDF Downloads 22 22 4
EPUB Downloads 0 0 0